Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations
Autore:
Imai, M; Jobo, T; Sato, R; Kawaguchi, M; Kuramoto, H;
Indirizzi:
Kitasato Univ, Grad Sch Med Sci, Dept Clin Cytol, Sagamihara, Kanagawa 228, Japan Kitasato Univ Sagamihara Kanagawa Japan 228 gamihara, Kanagawa 228, Japan Kitasato Univ, Sch Med, Dept Obstet & Gynecol, Sagamihara, Kanagawa 228, Japan Kitasato Univ Sagamihara Kanagawa Japan 228 gamihara, Kanagawa 228, Japan
Titolo Testata:
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
fascicolo: 3, volume: 22, anno: 2001,
pagine: 217 - 220
SICI:
0392-2936(2001)22:3<217:MATFPW>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONSERVATIVE TREATMENT; PREMENOPAUSAL WOMEN; CARCINOMA; HYPERPLASIA; PREGNANCY; PROGESTIN; CANCER; AGE;
Keywords:
endometrial carcinoma; medroxyprogesterone acetate; fertility;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Imai, M Kitasato Univ, Grad Sch Med Sci, Dept Clin Cytol, 1-15-1 Kitasato,Sagamihara, Kanagawa 228, Japan Kitasato Univ 1-15-1 Kitasato Sagamihara Kanagawa Japan 228 Japan
Citazione:
M. Imai et al., "Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations", EUR J GYN O, 22(3), 2001, pp. 217-220

Abstract

Background: To determine the effectiveness of medroxyprogesterone acetate therapy for women with endometrial adenocarcinoma who wish to preserve their uterus. Study design: Fifteen patients with endometrial carcinoma (12 with grade 1endometrioid adenocarcinoma, 2 with grade 2 adenocarcinoma and 1 with adenoacanthoma) were treated with high-dose medroxyprogesterone acetate alone as primary therapy and their clinical responses evaluated. Results: Seven of the 12 cases (58%) with grade 1 adenocarcinoma and one of the two (50%) with grade 2 carcinoma responded initially to medroxyprogesterone acetate. The median length of treatment required for regression was 29 weeks. Three patients who initially responded relapsed. Thirteen patients are alive without evidence of disease as of December 1999 (10 to 146 months, median; 4 years and 11 months) and one is continuing medroxyprogesterone acetate therapy as a final follow-up. One patient was lost to follow-up. Two patients have conceived having three healthy infants. Conclusion: Treatment of endometrial carcinoma with high-dose medroxyprogesterone acetate could be an alternative to hysterectomy, although the successful rate is limited.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 11:45:41